IMPORTANCE Non-vitamin K antagonist oral anticoagulants (NOACs) might be an attractive choice for stroke prevention in people without atrial fibrillation who may harbor a potential source of cardiac emboli, but not if certain individual NOACs carry risks of intracranial hemorrhage that are heightened relative to aspirin.
I ntracranial hemorrhage is a major concern when an antithrombotic agent is given to a patient, because intracranial hemorrhage is generally associated with a high risk of mortality 1 and poorer health over a lifetime, 2,3 which could offset the benefits of antithrombotic treatment in reducing major ischemic events. Such a concern may lead some physicians to resort to aspirin in certain situations, such as atrial fibrillation, when an oral anticoagulant is indicated. However, in a large clinical trial of patients with atrial fibrillation, 4 a 5-mg dose of apixaban twice daily was shown to not cause more intracranial hemorrhage than aspirin, and the medication substantially reduced stroke risk, thereby making aspirin, with its much smaller stroke protection benefit, no longer a viable therapeutic option in people with atrial fibrillation, even from a standpoint of safety concern. Considering the low risks of intracranial hemorrhage with non-vitamin K antagonist oral anticoagulants (NOACs) use, one may wonder whether NOACs could be applied to clinical scenarios beyond atrial fibrillation that traditionally been treated by aspirin. However, NOACs are not all the same. A network meta-analysis comparing one NOAC with another clearly show they are different in terms of effectiveness and safety. 5 Indeed, another large clinical trial showed that a 15-mg dose of rivaroxaban once daily substantially increased the risk of intracranial hemorrhage in patients with embolic stroke of undetermined source. 6 Although NOACs and aspirin are in general protective in different vascular beds, NOACs might be an attractive choice for stroke prevention in certain clinical situations, such as in people without recognized atrial fibrillation but with an embolic stroke of undetermined source 7, 8 or atrial cardiopathy [9] [10] [11] because of their propensity to also cause stroke through cardiac emboli. Nonetheless, the benefit of NOACs compared with aspirin for stroke protection is likely to be less promising in people without atrial fibrillation, compared with people with atrial fibrillation. Therefore it is even more important to clarify whether individual NOACs in various doses harbor comparable risks of intracranial hemorrhage with aspirin based on the evidence currently available before conducting a large clinical trial in such a population. To do this, we conducted a systematic review and meta-analysis of randomized clinical trials for the comparison across all indications of intracranial hemorrhage with individual NOACs vs aspirin.
Methods
This study was performed in accordance with the recommendations of the Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) statement. 12 
Data Sources and Searches
We 
Study Selection
Criteria for inclusion of a study were (1) a randomized clinical trial study design, (2) inclusion of a comparison of NOACs with aspirin, (3) reporting of intracranial hemorrhage as an end point, (4) reporting of the number of participants and the number of intracranial hemorrhage separately in each group, and (5) a treatment duration of at least 3 months. When comparison of individual NOACs (eg, dabigatran and edoxaban) with aspirin were not available, we selected studies comparing dabigatran or edoxaban with warfarin, as well as comparing aspirin with warfarin, to obtain the indirect comparison between dabigatran or edoxaban and aspirin. Criteria for exclusion of a study were that it (1) was an NOAC trial that did not use at least of 1 of the 4 eligible NOACs (ie, dabigatran, rivaroxaban, apixaban, and edoxaban), because only these NOACs are approved for use in atrial fibrillation in current guidelines; (2) included a combination of 2 or more antithrombotic agents as a treatment strategy in a study arm; (3) used antiplatelet agents other than aspirin; and (4) was published prior to 2000. In addition, we excluded all studies that included a population in which most participants had (5) cancer; (6) a mechanic heart valve (because the use of 1 NOAC, dabigatran, in patients with mechanical heart valves was associated with increased rates of thromboembolic and bleeding complications compared with warfarin, and NOAC use is thus not justified for these patients 13 ); or (7) end-stage renal disease.
Data Abstraction
We abstracted data about baseline characteristics, which include age, sex, duration of follow-up, and the number of patients in each group. We also abstracted data on safety outcomes from each trial, which include numbers with intracranial hemorrhage, major bleeding, and fatal bleeding in each group under NOACs and aspirin treatment. Two investigators (M.L. and W.-Y.H.) independently abstracted data from eligible studies. Any discrepant judgments were resolved by joint discussion.
Quality Assessment
The risk of bias (eg, sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other issues) in each trial was independently assessed in accordance with the Cochrane risk of bias tool. The risk of bias was rated as low, unclear, or high, according to established criteria. 14 
Statistical Analysis
The primary end point was the association of individual NOACs (compared with aspirin) with risks for intracranial hemorrhage. The secondary end points were risks of major bleeding and fatal bleeding. The definitions of intracranial hemorrhage and fatal bleeding were consistent across trials. (Intracranial hemorrhage was defined as traumatic and atraumatic intracerebral, subarachnoid, and subdural or epidural hemorrhage. Fatal bleeding was defined as mortality caused by bleeding.) However, major bleeding differed slightly across trials. It was defined as clinically overt bleeding accompanied by 1 or more of the following: a decrease in the hemoglobin level of 2 g/dL or more in a 24-hour period, transfusion of 2 or more units of packed red cells, and bleeding at a critical site 4 or any site in the body, 6 as per the criteria of the International Society of Thrombosis and Hemostasis. The dosage of each NOAC was taken into consideration. Rivaroxaban was further categorized into 15 to 20 mg once daily and 10 mg once daily or 5 mg twice daily, because this difference of dosage was substantial.
Odds ratios (OR) with 95% CIs were used as a measure of the association of individual NOACs vs aspirin with the risk of intracranial hemorrhage, fatal bleeding, or major bleeding. We computed a fixed-effect estimate based on the Mantel-Haenszel method when 2 or more studies provided suficient data for a given outcome. The principal analysis was pairwise comparisons between individual NOACs and aspirin.
In situations where pairwise comparisons were not available between certain NOACs (ie, dabigatran and edoxaban) and aspirin, we conducted accessory analyses using dabigatran or edoxaban vs warfarin and aspirin vs warfarin to obtain indirect comparisons of dabigatran or edoxaban vs aspirin. Results from these indirect comparisons should be regarded as suggestive rather than conclusive. Studies that compared rivaroxaban or apixaban with warfarin were excluded from the study; because direct comparison between rivaroxaban or apixaban vs aspirin has been available in randomized clinical trials, it was not necessary to obtain results from indirect comparison.
Subgroup analyses for the primary end point, intracranial hemorrhage, were conducted for different trial characteristics: patients with a history of ischemic stroke, atrial fibrillation, or venous thromboembolism at entry. This subgroup analysis was driven by the fact that the risk of intracranial hemorrhage within 1 year after ischemic stroke is about 15 times higher than in the reference population, 15 and patients with atrial fibrillation have a propensity to have more incidents of bleeding compared with patients without atrial fibrillation. 16 Therefore it was important to clarify whether individual NOACs were causing additional risks of intracranial hemorrhage compared with aspirin in these situations. Heterogeneity was assessed by the P value of χ 2 and I 2 statistics, which describes the percentage of variability in the effect estimates that is because of heterogeneity rather than chance. 17, 18 We considered study-level estimates to be heterogeneous if the χ 2 test was signiicant (P < .05) or the I 2 statistic was greater than 50%. We report absolute risks in terms of the difference in the number of events per 1000 patients and the respective 95% CI. All analyses were based on the intentionto-treat principle. We evaluated the quality of evidence for primary and secondary outcomes reported in the meta-analysis. 19 For all analyses, P < .05 was considered statistically significant. The Review Manager Software Package (RevMan 5; Cochrane Collaboration) and Stata version 13 (Stata Corp) were used for this meta-analysis.
Results
The literature review identified 56 full articles for detailed assessment, of which 31 were excluded for using placebo or no treatment in the control group (k = 4), using another antiplatelet drug rather than aspirin in the comparator group (k = 2), continuing treatment for less than 3 months (k = 19), or comparing rivaroxaban or apixaban with warfarin (k = 6). Twenty trials regarding dabigatran or edoxaban vs warfarin and aspirin vs warfarin were included in accessory analyses for the purpose of obtaining indirect comparisons of dabigatran or edoxaban vs aspirin. Our final principal analysis included 5 randomized clinical trials comparing NOAC and aspirin, with 39 398 individuals enrolled (eFigure in the Supplement). 4, 6, [20] [21] [22] One trial 4 compared a 5-mg dose of apixaban twice daily with aspirin in patients with atrial fibrillation. One trial 6 compared 15 mg of rivaroxaban once daily with aspirin in patients with embolic stroke of undetermined source. One trial 22 compared rivaroxaban delivered in 20-mg or 10-mg doses once daily with aspirin in patients with venous thromboembolism. Two trials compared a 5-mg dose of rivaroxaban twice daily with aspirin in patients with stable cardiovascular disease 20 and stable peripheral or carotid artery disease.
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The characteristics of these 5 randomized clinical trials are shown in Table 1 . The overall quality of included trials was considered good, because all trials showed low risk of bias based on the Cochrane risk of bias assessment (eTable 1 in the Supplement). Figure 1) .
A 15-mg to 20-mg dose of rivaroxaban once daily, compared with aspirin, would cause an additional 3 intracranial a This study used apixaban in the active study arm.
b These studies used rivaroxaban in the active study arm.
hemorrhage per 1000 patients who receive it. The quality of a body of evidence was moderate ( 20 -mg dose of rivaroxaban once daily and a 10-mg dose once daily or a 5-mg dose twice daily would cause an additional 9 major bleeding events in 1000 patients compared with aspirin use alone. The quality of a body of evidence was found to be moderate to high (Table 2) .
Subgroup Analysis
Subgroup analysis for intracranial hemorrhage was presented in Figure 2 . For patients with stroke at study entry, a 15-mg dose of rivaroxaban once daily vs aspirin was associated with increased risks of intracranial hemorrhage (OR, 4 
Accessory Analysis
There was no direct comparison of dabigatran or edoxaban vs aspirin. Therefore, 20 trials regarding dabigatran vs warfarin, edoxaban vs warfarin, and aspirin vs warfarin were included for the purpose of obtaining the indirect comparison of dabigatran or edoxaban vs aspirin (eTable 2 in the Supplement). Indirect comparison implied both dabigatran at a dose of 110 mg to 150 mg twice daily and edoxaban at a dose of 30 to 60 mg once daily might be not associated with increased risks of intracranial hemorrhage or fatal bleeding compared with aspirin but might be associated with increased risks of major bleeding (eTable 3 in the Supplement).
Discussion
In this meta-analysis of 5 randomized clinical trials across all indication of high-quality data from almost 40 000 people, we found that a 15-mg to 20-mg dose of rivaroxaban once daily was associated with substantially higher odds of intracranial hemorrhage than aspirin, while a 5-mg dose of apixaban twice daily and a 10-mg dose of rivaroxaban once daily or a 5-mg dose twice daily were not associated with increased risks. The quality of a body of evidence for outcome was moderate. Although the results were derived from a few (even single) large randomized clinical trials, it might provide evidence to inform the potential design and conduct of future NOAC trials beyond atrial fibrillation. Also, indirect comparisons implied that dabigatran in doses of 110 mg to 150 mg twice daily and edoxaban in doses of 30 mg to 60 mg once daily might have comparable risks of intracranial hemorrhage with aspirin, although such results should be interpreted with caution because of the lack of head-to-head comparisons in any randomized clinical trial. The novelty of this meta-analysis lies in the comparison across all indications of intracranial hemorrhage with individual NOAC vs aspirin. The efficacy and safety of NOACs as a class in patients with atrial fibrillation has been well established. 24 However, the risk of intracranial hemorrhage possessed by each individual NOAC is crucial when that NOAC is to be considered in a clinical scenario other than treatment of a patient with atrial fibrillation. For example, several large prospective cohorts have shown that atrial abnormality was associated with increased risks of stroke in patients without recognized atrial fibrillation. [9] [10] [11] Patients with ischemic stroke who do not have atrial fibrillation but do have moderate to severe left atrial enlargement (vs normal left atrial size) also show a trend toward a greater risk of recurrent cardioembolic or cryptogenic stroke. 25 Although cardiac emboli are likely to be the cause for stroke, those patients would be treated by aspirin unless atrial fibrillation is recognized. Since a 5-mg dose of apixaban twice daily had comparable risks of intracranial hemorrhage with aspirin, it could be an attractive alternative agent for use on this population. On the other hand, a 15-mg to 20-mg dose of rivaroxaban once daily possessed substantial higher risks of intracranial hemorrhage than aspirin, its use in people without atrial fibrillation could not be encouraged. Although 10 mg of rivaroxaban once daily or 5 mg twice daily did not show higher risks of intracranial hemorrhage than aspirin in this meta-analysis, it is worthwhile to mention that such lowdose rivaroxaban did not reduce major cardiovascular events or stroke compared with aspirin in patients with vascular disease, 20, 21 and even a 15-mg dose of rivaroxaban was not better than aspirin for recurrent ischemic stroke prevention among embolic stroke patients without recognized atrial fibrillation. 6 
Limitations
This study has several limitations. First, a meta-analysis may be biased when the literature search fails to identify all relevant trials or the selection criteria for including a trial are applied in a subjective manner. To minimize these risks, we performed thorough searches across multiple literature and trial databases and used explicit criteria for study selection, data abstraction, and data analysis.
Second, the results were derived from a few large clinical trials, and in some cases from single trials, and the quality of a body of evidence was moderate. Also, there is to our knowledge no pairwise comparison in dabigatran or edoxaban vs aspirin in a published randomized clinical trial to date. Ongoing trials with apixaban vs aspirin 8 and dabigatran vs aspirin 7 in patients with embolic stroke with undetermined source may help to resolve these concerns, at least partially. Third, intracerebral hemorrhage is known to account for a larger proportion of strokes in Asian vs white populations, 26, 27 and thus it is important to clarify the risks of intracranial hemorrhage between individual NOACs and aspirin in Asian individuals. However, no trials included in this analysis provided ethnic subgroup analysis, and for this reason, further analysis was not possible.
Finally, in this study-level meta-analysis, we were only able to use data on major bleeding provided by the original trials, which used a variety of differing definitions. Because major bleeding was the secondary end point of this study and the differences in definitions was not substantial, this likely made little difference in the overall results of this meta-analysis.
Conclusion
In conclusion, in this meta-analysis of randomized clinical trials across all indications comparing individual NOACs and aspirin, we found that patients receiving 15 to 20 mg of rivaroxaban once daily had substantially increased risks of intracranial hemorrhage, while patients who took 10 mg of rivaroxaban once daily, 5 mg of rivaroxaban twice daily, or 5 mg of apixaban twice daily had no increased risks. There was no pairwise comparison between dabigatran or edoxaban vs aspirin, but an indirect comparison suggests that taking 110 to 150 mg of dabigatran twice daily or 30 to 60 mg of edoxaban once daily might be not associated with increased risks of intracranial hemorrhage, although such results should be interpreted with caution. Based on these findings, only patients with atrial fibrillation should be considered for administration of 15 to 20 mg of rivaroxaban once daily. In addition, it may be worthwhile to conduct randomized clinical trials comparing certain NOAC dosages (eg, 5 mg of apixaban twice daily) and aspirin in patients who do not have atrial fibrillation but do have potential sources of cardiac emboli that can cause stroke. 
